Tropical Diseases Travel Medicine and Vaccines, published by SPRINGERNATURE, stands at the forefront of research in the fields of infectious diseases and public health, with an impressive impact factor that signifies its relevance and influence. Since its inception in 2015, this peer-reviewed journal has maintained an open access policy, ensuring that cutting-edge research on tropical diseases and travel medicine is readily available to researchers, professionals, and students worldwide. The journal currently ranks in the Q2 Quartile for both Infectious Diseases and Public Health, Environmental and Occupational Health, reflecting its substantial contribution to these critical areas of study. With a strong Scopus rank of #176 in Public Health and #138 in Infectious Diseases, it serves as a vital platform for innovative studies that advance understanding and response strategies related to tropical diseases. For its vast audience, Tropical Diseases Travel Medicine and Vaccines not only acts as a bridge connecting researchers with practical applications but also nurtures academic discourse essential for future advancements in global health.

MICROBIOLOGY AND IMMUNOLOGY, an esteemed journal published by WILEY, serves as a vital resource for researchers and professionals in the fields of microbiology, immunology, and virology. With its ISSN 0385-5600 and E-ISSN 1348-0421, this journal has been a cornerstone in scientific literature since its inception in 1977, bridging decades of research and innovation through its comprehensive coverage of emerging trends and discoveries. Although this journal operates without open access, it maintains a commendable presence in academic circles, reflected in its 2023 Quartile rankings of Q3 across the categories of Immunology, Microbiology, and Virology. As part of an important discourse in these disciplines, MICROBIOLOGY AND IMMUNOLOGY ensures its scholarly contributions are relevant to both seasoned researchers and emerging scholars. Positioned in a competitive journal landscape, with Scopus ranks indicating a median percentile across its fields, it remains committed to advancing knowledge through peer-reviewed articles, thereby supporting the continuous evolution of its focus areas. The journal's current scope encompasses topics critical for understanding pathogen-host interactions and the immune response, making it a crucial publication for any academic library or individual scholar dedicated to the biological sciences.

Eurosurveillance is a prestigious journal dedicated to the field of epidemiology, public health, and infectious diseases, published by the European Centre for Disease Prevention and Control since 1996. With an impressive Q1 ranking across various categories, including Epidemiology and Public Health, it consistently stands at the forefront of research dissemination, making it an invaluable resource for researchers, professionals, and students alike. The journal boasts an outstanding reputation, as evidenced by its Scopus rankings, where it ranks in the top 1% to 3% in multiple relevant categories. As an Open Access publication, Eurosurveillance ensures that vital findings are freely accessible to a global audience, fostering collaboration and innovation in the fight against infectious diseases. With a dedicated reach from 2001 to 2024, the journal addresses contemporary challenges in public health and virology, reinforcing its significance in shaping policies and research initiatives across the world.

Open Forum Infectious Diseases (ISSN: 2328-8957; E-ISSN: 2328-8957) is a leading open-access journal published by Oxford University Press, dedicated to advancing the field of infectious diseases. Since its inception in 2014, the journal has provided a platform for researchers to disseminate impactful findings in a rapidly evolving domain, achieving a remarkable Q1 ranking in both the Infectious Diseases and Oncology categories as of 2023. The journal encourages rigorous and innovative research, contributing significantly to global health discussions and informing best practices in clinical settings. As an open-access journal, it ensures that its content is accessible to a wide audience, fostering collaboration and knowledge sharing among researchers, professionals, and students alike. Positioned in the heart of the United States, Open Forum Infectious Diseases serves as a critical resource for the academic community, and its continued commitment to quality and relevance secures its status as an essential publication in the field.

Vaccine is a premier academic journal published by Elsevier Science Ltd, dedicated to the field of vaccination and immunization research. With an impact factor and H-index that underscore its significance in the scientific community, this journal has consistently ranked in the Q1 category within various fields, including Immunology and Microbiology, Infectious Diseases, and Public Health. Since its inception in 1983, it has served as a vital resource for researchers, healthcare professionals, and students, providing rigorous peer-reviewed articles that explore important breakthroughs and innovations in vaccine development and deployment. Although it does not operate under an Open Access model, the journal maintains high visibility within academic circles, thanks to its strategic collaborations and widely respected editorial board. By bridging the gaps between laboratory discoveries and clinical applications, Vaccine plays a crucial role in advancing global health initiatives and addressing urgent public health challenges.

Viral Immunology, published by Mary Ann Liebert, Inc, stands as a prominent journal dedicated to advancing the understanding of the interplay between viral infections and host immune responses. With a strong focus on immunology, molecular medicine, and virology, the journal provides a platform for the dissemination of high-quality research findings and innovative methodologies that could shape the future of these critical fields. Although it currently holds a Q3 rating across its relevant categories and a respectable ranking within the Scopus database, Viral Immunology continues to strive for excellence with a commitment to publishing influential research that informs both academic and clinical practices. The journal accepts submissions in various formats—original research, reviews, and commentaries—catering to a diverse readership that includes researchers, professionals, and students engaged in the biological and medical sciences. Readers can anticipate insightful articles that address urgent challenges in immunological responses to viral infections, paving the way for new therapeutic strategies and public health initiatives.

Future Virology, published by Future Medicine Ltd, is an essential journal dedicated to advancing the understanding of virology in the contemporary scientific landscape. With an ISSN of 1746-0794 and an E-ISSN of 1746-0808, this journal serves as a platform for researchers and practitioners in the field to publish high-quality, peer-reviewed articles that explore novel discoveries, innovative therapeutic strategies, and the implications of viral research on global health. Operating from the United Kingdom and maintaining a commitment to rigorous scientific inquiry, Future Virology is categorized in the Q4 Quartile for Virology according to the latest Scopus rankings, with a position of Rank #48/80 and a percentile of 40th in the Virology category. Although it currently does not offer open access, the journal strives to disseminate critical insights that benefit a wide range of professionals, researchers, and students engaged in virology and related fields. By bridging the gap between basic research and practical applications, Future Virology plays a crucial role in fostering innovation and collaboration in the ever-evolving virology landscape.

SEXUALLY TRANSMITTED DISEASES is a premier academic journal published by Lippincott Williams & Wilkins, dedicated to the investigation and dissemination of research on sexually transmitted infections and related public health issues. This journal, with the ISSN 0148-5717 and E-ISSN 1537-4521, has been a cornerstone of the field since its inception in 1977, with coverage extended to 2024. A testament to its scholarly impact, it holds prestigious rankings in the top quartiles across various categories including Q1 in Dermatology and Q1 in Public Health, Environmental and Occupational Health, underscoring its importance in driving forward critical discussions and advancements in these vital areas of health. With an emphasis on rigorous research and the latest scientific findings, the journal not only serves researchers and professionals but also informs clinical practices, shaping public health policies. While it is not an Open Access journal, it offers a wealth of subscription-based resources highly regarded for their quality and relevance within the medical community.

Vaccine: X, published by Elsevier, is a premier open access journal dedicated to advancing research in the interdisciplinary fields of immunology and microbiology, infectious diseases, molecular medicine, and public health. With an ISSN of 2590-1362 and operating since 2019, the journal has rapidly established an influential role, achieving Q2 rankings in major categories such as Immunology and Microbiology, Infectious Diseases, and Public Health for 2023. Its commitment to disseminating cutting-edge research is evident from its broad scope, focusing on innovative vaccines and therapies that are critical for global health. Researchers and professionals will find value in the accessible nature of the journal, which has been recognized for its contributions to veterinary medicine as well, with a Q1 ranking in the miscellaneous veterinary category. The journal proudly showcases high-quality, peer-reviewed articles and welcomes submissions that push the boundaries of current knowledge, making it an essential resource for anyone involved in vaccine research and development.

Infektsiya i Immunitet, published by the esteemed SANKT-PETERSBURG-NIIEM IMENI PASTERA, is a prominent open access journal that has been disseminating vital research findings since 2011. Focusing on the fields of immunology and infectious diseases, this journal serves as a critical platform for scholars, professionals, and students in the Russian Federation and beyond. With an ISSN of 2220-7619 and an E-ISSN of 2313-7398, it currently holds a Q4 ranking in 2023 for both Immunology and Infectious Diseases, along with notable quartile standings in related fields. Despite its emerging status, Infektsiya i Immunitet provides valuable insights and contributes to the growing discourse on immunity and infection prevention strategies, making it an essential resource for those invested in advancing knowledge and enhancing public health outcomes. Researchers can conveniently access its wealth of articles and studies that bridge theoretical understanding and practical implications in their respective domains.